<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="influenza B samples from influenza-like illness (ILI) outpatients and severe" exact="acute" post="respiratory illness (SARI) inpatients detected in sentinel hospitals in"/>
 <result pre="B samples from influenza-like illness (ILI) outpatients and severe acute" exact="respiratory" post="illness (SARI) inpatients detected in sentinel hospitals in Uruguay"/>
 <result pre="5–14 years constituted the majority (33%) of all influenza B" exact="infection" post="(p &amp;lt; 0.05). Interestingly, we found that individuals &amp;gt;25"/>
 <result pre="the society. An estimated of more than 290,000 seasonal influenza-associated" exact="respiratory" post="deaths annually occur worldwide [1]. In the American region,"/>
 <result pre="seasonal influenza-associated respiratory deaths annually occur worldwide [1]. In the" exact="American" post="region, each year, an average of 772,000 respiratory hospitalizations"/>
 <result pre="In the American region, each year, an average of 772,000" exact="respiratory" post="hospitalizations is attributed to influenza virus [2]. Although influenza"/>
 <result pre="in the 1940s and, unlike influenza A, they primarily cause" exact="disease" post="in humans [7]. Recurrent seasonal epidemics are the consequence"/>
 <result pre="unlike influenza A, they primarily cause disease in humans [7]." exact="Recurrent" post="seasonal epidemics are the consequence of the antigenic drift,"/>
 <result pre="lineage viruses, including younger average ages of persons with Victoria" exact="virus infection" post="and greater transmissibility. The Victoria lineage is under greater"/>
 <result pre="viruses, including younger average ages of persons with Victoria virus" exact="infection" post="and greater transmissibility. The Victoria lineage is under greater"/>
 <result pre="observe the existence of possible known substitutions that cause reduced" exact="susceptibility to" post="neuraminidase inhibitors (NAI). 2. Materials and Methods 2.1. Influenza"/>
 <result pre="Health, is the Reference Laboratory for Influenza and other non-Influenza" exact="respiratory" post="viruses. Uruguay is a country with a temperate climate,"/>
 <result pre="is a country with a temperate climate, where outbreaks of" exact="respiratory" post="viruses usually occur mainly in the autumn-winter period, between"/>
 <result pre="swabs that were obtained from 5299 hospitalized patients with severe" exact="acute" post="respiratory infection (SARI) associated with influenza and 455 outpatients"/>
 <result pre="that were obtained from 5299 hospitalized patients with severe acute" exact="respiratory" post="infection (SARI) associated with influenza and 455 outpatients with"/>
 <result pre="were obtained from 5299 hospitalized patients with severe acute respiratory" exact="infection" post="(SARI) associated with influenza and 455 outpatients with clinical"/>
 <result pre="clinical samples that were stored at −80 °C, using QIAamp" exact="Viral" post="RNA mini kit (Qiagen), according to the manufacturer´s suggested"/>
 <result pre="sets of primers and probes were provided by Centers for" exact="Disease" post="Control and Prevention (CDC, USA). Testing was done according"/>
 <result pre="reverse transcriptase), 0.5 μL of RNAsin, and 5 μL of" exact="viral" post="RNA extract. The RT-PCR reaction was carried out in"/>
 <result pre="NA gene, a specific primer set was designed for the" exact="partial" post="amplification of the NA gene (position 168−1386 bp). Briefly,"/>
 <result pre="(Taq DNA polymerase and reverse transcriptase), and 5 μL of" exact="viral" post="RNA extract. The RT-PCR reaction was carried out in"/>
 <result pre="and 1108 nt for the NA gene. 2.6. Phylogenetic Analysis" exact="Multiple" post="sequence alignment was performed by using the Muscle method"/>
 <result pre="Phylogenetic Analysis Multiple sequence alignment was performed by using the" exact="Muscle" post="method implemented in Mega program (v 6.06) (http://www.megasoftware.net/) [17]."/>
 <result pre="Distribution among Type of Surveillance From 2012 to 2019, a" exact="total" post="of 5299 SARI and 455 ILI cases were reported."/>
 <result pre="Viruses In the eight-year period studied, the NIC received a" exact="total" post="of 5754 samples from the sentinel surveillance. Of these"/>
 <result pre="217 IBV ranged from newborn to 88-year old. Influenza B" exact="infection" post="was widely distributed across age-groups, with a clear predominance"/>
 <result pre="predominance in children and teenagers with more than 60% of" exact="total" post="influenza B infections. Those between 5–14 years had the"/>
 <result pre="in 2013 and 2016, the lowest incidence of influenza B" exact="virus infection" post="was detected (2.8% and 4.5%, respectively), along with the"/>
 <result pre="2013 and 2016, the lowest incidence of influenza B virus" exact="infection" post="was detected (2.8% and 4.5%, respectively), along with the"/>
 <result pre="in the trivalent influenza vaccine (TIV) for that season. A" exact="partial" post="mismatch was defined if both lineages co-circulated at equal"/>
 <result pre="mismatched to the vaccine strain was calculated based in the" exact="total" post="number of successfully lineage-typed specimens. During 2012–2019, a high"/>
 <result pre="vaccine strain during 2012, 2013, and 2015. During 2017, a" exact="partial" post="mismatch (Victoria 57%, Yamagata 43%) was observed, being the"/>
 <result pre="of the HA Gene of Uruguayan Influenza B Viruses The" exact="complete" post="HA1 region of the HA gene were obtained from"/>
 <result pre="influenza B sequences were obtained from GISAID database. Hence, a" exact="total" post="of 63 HA influenza B sequences from 208 positive"/>
 <result pre="of the NA Gene of Uruguayan Influenza B Viruses A" exact="partial" post="region of the NA gene was obtained from 27/41"/>
 <result pre="influenza B sequences were obtained from GISAID database. Hence, a" exact="total" post="of 51 NA influenza B sequences from 208 positive"/>
 <result pre="6 and Figure 7). Mutation Screening for Influenza B Virus" exact="Resistance" post="to NA Inhibitors Influenza NA is a surface glycoprotein"/>
 <result pre="influenza NA does not avoid disease, but it treats influenza" exact="disease" post="and might shorten the symptoms. We analyzed the NA"/>
 <result pre="still be suitable as a first-line treatment of influenza B" exact="infections" post="in Uruguay. 4. Discussion Until the present study, there"/>
 <result pre="that suggest that influenza B virus contribute significantly to influenza" exact="disease" post="[3,28,29,30,31,32,33]. Our findings revealed that types A and B"/>
 <result pre="important role of influenza B virus in the spread of" exact="infection" post="in the population. In a study by Glezen P"/>
 <result pre="In 2013 and 2016, the lowest incidence of influenza B" exact="virus infection" post="was detected in Uruguay, along with the highest incidence"/>
 <result pre="2013 and 2016, the lowest incidence of influenza B virus" exact="infection" post="was detected in Uruguay, along with the highest incidence"/>
 <result pre="along with the highest incidence of influenza A/H1N1 pdm09. The" exact="absence of" post="influenza B viruses in some season is not unusual,"/>
 <result pre="colleagues [12] proposed that age difference between Victoria and Yamagata-lineage" exact="infections" post="is thought to be due to differences in the"/>
 <result pre="which help the viruses to infect the epithelium of the" exact="respiratory" post="tract, while Orsi and colleagues [45] proposed a higher"/>
 <result pre="well known that SARI cases in children could lead to" exact="respiratory" post="failure. Respiratory Sincitial Virus (RSV) and human Metapneumovirus (hMPV)"/>
 <result pre="that SARI cases in children could lead to respiratory failure." exact="Respiratory" post="Sincitial Virus (RSV) and human Metapneumovirus (hMPV) significantly increase"/>
 <result pre="have demonstrated that influenza played an important role in the" exact="viral" post="aetiologies of ILI cases [49,50], while other respiratory viruses"/>
 <result pre="in the viral aetiologies of ILI cases [49,50], while other" exact="respiratory" post="viruses were essential for the cause of SARI, especially"/>
 <result pre="further in 2018 and prevailing in 2019 in the South" exact="American" post="region. The Yamagata lineage can be subdivided into clades"/>
 <result pre="than in Yamagata lineage viruses [53]. The hemagglutinin represents a" exact="primary" post="target for host neutralizing antibodies. More specifically, the HA1"/>
 <result pre="regions [57]. Amino acid changes in these regions may alter" exact="viral" post="antigenicity, and potentially change the evolution direction as new"/>
 <result pre="lineages evolve [54]. These mutations may have contributed to increasing" exact="viral" post="fitness. If they contributed to antigenic evolution, changes in"/>
 <result pre="and NA) be balanced to efficiently maintain the capacity for" exact="infection" post="and the release of viral particles [58]. Compensatory mutations"/>
 <result pre="efficiently maintain the capacity for infection and the release of" exact="viral" post="particles [58]. Compensatory mutations that maintain the replicative capacities"/>
 <result pre="preventive measure for reducing the incidence and severity of the" exact="disease" post="[63]. The selection of the influenza B virus strain"/>
 <result pre="2015. Our data showed that 28% of the influenza B" exact="infections" post="that circulated in Uruguay did not correspond to the"/>
 <result pre="vaccine-based preventive measures, with potential to reduce the burden of" exact="disease" post="in vaccinated and unvaccinated individuals. However so far, only"/>
 <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
 <result pre="of interest. References References 1.IulianoA.D.RoguskiK.M.ChangH.H.MuscatelloD.J.PalekarR.TempiaS.CoenC.GranJ.M.SchanzerD.CowlingB.J.et al.Estimates of global seasonal influenza-associated" exact="respiratory" post="mortality: A modeling studyLancet20183911285130010.1016/S0140-6736(17)33293-229248255 2.PalekarR.RolfesM.ArriolaC.AcostaB.AlbertoP.BadillaX.BancejC.BarbozaJ.BaumeisterE.BrunoA.et al.Burden of influenza-associated respiratory"/>
 <result pre="influenza-associated respiratory mortality: A modeling studyLancet20183911285130010.1016/S0140-6736(17)33293-229248255 2.PalekarR.RolfesM.ArriolaC.AcostaB.AlbertoP.BadillaX.BancejC.BarbozaJ.BaumeisterE.BrunoA.et al.Burden of influenza-associated" exact="respiratory" post="hospitalizations in the Americas, 2010-2015PLoS ONE201910.1371/journal.pone.022147931490961 3.CainiS.AlonsW.J.BalmasedaA.BrunoA.BustosP.CastilloL.de LozanoC.de MoraD.FasceR.FerreriraW.et"/>
 <result pre="Public Health.201310.2105/AJPH.2012 5.JenningsL.HuangQ.BarrI.LeeP.KimW.J.BuchyP.SanicasM.MungalyB.ChenJ.Literature review of the epidemiology of influenza B" exact="disease" post="in 15 countries in the Asia-Pacific regiónInfluenza Other Respir."/>
 <result pre="molecular evolutionElife201410.7554/eLife.01914 9.RotaP.A.WallisT.R.HarmonM.W.RotaJ.S.KendalA.P.NeromeK.Cocirculation of two distinct evolutionary lineages of influenza" exact="type B" post="virus since 1983Virology1990175596810.1016/0042-6822(90)90186-U2309452 10.LoY.-C.ChuangJ.-H.KuoH.-W.HuangW.T.HsuY.F.LiuM.T.ChenC.H.HuangH.H.ChangC.H.ChouJ.H.et al.Surveillance and vaccine effectiveness of"/>
 <result pre="substitutions in the influenza neuraminidase associated with resistance or reduced" exact="susceptibility to" post="NAIsAvailable online: https://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/nai_overview/en/(accessed on 20 January 2020) 26.GoñiN.BazM.RuchanskyD.CoppolaL.RussiJ.C.CristinaJ.Influenza B"/>
 <result pre="strain matchVirus Res.200712310010410.1016/j.virusres.2006.08.00216987563 27.HortalM.RussiJ.C.ArbizaJ.R.CanepaE.ChiparelliH.IlarramendiA.Identification of viruses in a study of" exact="acute" post="respiratory tract infection in children from UruguayRev. Infect. Dis.199012S995S99710.1093/clinids/12.Supplement_8.S9952270420"/>
 <result pre="matchVirus Res.200712310010410.1016/j.virusres.2006.08.00216987563 27.HortalM.RussiJ.C.ArbizaJ.R.CanepaE.ChiparelliH.IlarramendiA.Identification of viruses in a study of acute" exact="respiratory" post="tract infection in children from UruguayRev. Infect. Dis.199012S995S99710.1093/clinids/12.Supplement_8.S9952270420 28.PalekarR.RodriguezA.AvilaC.BarreraG.BarreraM.BrenesH.BrunoA.El"/>
 <result pre="27.HortalM.RussiJ.C.ArbizaJ.R.CanepaE.ChiparelliH.IlarramendiA.Identification of viruses in a study of acute respiratory tract" exact="infection" post="in children from UruguayRev. Infect. Dis.199012S995S99710.1093/clinids/12.Supplement_8.S9952270420 28.PalekarR.RodriguezA.AvilaC.BarreraG.BarreraM.BrenesH.BrunoA.El OmeiriN.FasceR.Ferreira de"/>
 <result pre="the Global Influenza B StudyInfluenza Other Respir. Viruses2015931210.1111/irv.1231926256290 32.BarrI.G.VijaykrishnaD.SullivanS.G.Differential age" exact="susceptibility to" post="influenza B/Victoria lineage viruses in the 2015 Australian influenza"/>
 <result pre="Virol.1999737343734810.1128/JVI.73.9.7343-7348.199910438823 35.BakerS.F.NogalesA.FinchC.TuffyK.M.DommW.PerezD.R.TophamD.J.Martínez-SobridoL.Influenza A and B virus intertypic reassortment through compatible" exact="viral" post="packaging signalsJ. Virol.201488107781079110.1128/JVI.01440-1425008914 36.DudasG.BedfordT.LycettS.RambautA.Reassortment between influenza B lineages and"/>
 <result pre="during 2011–2014PLoS ONE201610.1371/journal.pone.0158244 42.TrucchiC.AlicinoC.OrsiA.PaganinoC.BarberisI.GrammaticoF.CanepaP.RappazzoE.BruzzoneB.SticchiL.et al.Fifteen years of epidemiologic, virologic and" exact="syndromic" post="influenza surveillance: A focus on type B virus and"/>
 <result pre="of epidemiologic, virologic and syndromic influenza surveillance: A focus on" exact="type B" post="virus and the effects of vaccine mismatch in Liguria"/>
 <result pre="ONE20138e6429510.1371/journal.pone.006429523717587 51.ZhangC.ZhuN.XieZ.LuR.HeB.LiuC.MaX.TanW.Viral etiology and clinical profiles of children with severe" exact="acute" post="respiratory infections in ChinaPLoS ONE20138e7260610.1371/journal.pone.007260623991128 52.collab: World Health OrganizationRecommended"/>
 <result pre="51.ZhangC.ZhuN.XieZ.LuR.HeB.LiuC.MaX.TanW.Viral etiology and clinical profiles of children with severe acute" exact="respiratory" post="infections in ChinaPLoS ONE20138e7260610.1371/journal.pone.007260623991128 52.collab: World Health OrganizationRecommended composition"/>
 <result pre="etiology and clinical profiles of children with severe acute respiratory" exact="infections" post="in ChinaPLoS ONE20138e7260610.1371/journal.pone.007260623991128 52.collab: World Health OrganizationRecommended composition of"/>
 <result pre="of a community cohort, 2009-2015Clin. Infect. Dis.2017651532154110.1093/cid/cix56529020267 68.ReedC.ChavesS.S.KirleyP.D.EmersonR.AragonD.HancockE.B.ButlerL.HollickG.BaumbachJ.HollickG.et al.Estimating influenza" exact="disease" post="burden from population-based surveillance data in the United StatesPLoS"/>
 <result pre="data in the United StatesPLoS ONE201510e011836910.1371/journal.pone.011836925738736 69.collab: European Centre for" exact="Disease" post="Prevention and Control (ECDC)Immunization Schedules by Target DiseaseAvailable online:"/>
 <result pre="are indicated with arrows. Figure 6 Phylogenetic analysis of the" exact="partial" post="neuraminidase nucleotide sequences from influenza B Victoria-lineage viruses circulating"/>
 <result pre="are indicated with arrows. Figure 7 Phylogenetic analysis of the" exact="partial" post="neuraminidase nucleotide sequences from influenza B Yamagata-lineage viruses circulating"/>
 <result pre="with arrows. microorganisms-08-00591-t001_Table 1Table 1 Age distribution of influenza B" exact="infections" post="according to type of surveillance and influenza B lineages."/>
 <result pre="Pearson chi-square test and the median test. Samples Processed ILI" exact="Total" post="SARI Total IBV Total B/Vic B/Yam IBV Untyped *"/>
 <result pre="test and the median test. Samples Processed ILI Total SARI" exact="Total" post="IBV Total B/Vic B/Yam IBV Untyped * p-Value ILI"/>
 <result pre="the median test. Samples Processed ILI Total SARI Total IBV" exact="Total" post="B/Vic B/Yam IBV Untyped * p-Value ILI (+IBV) SARI"/>
 <result pre="years 834 20 814 34 10 19 5 0 33" exact="Total" post="5754 455 5299 217 110 98 9 44 172"/>
</results>
